Recombinant Syndecan 1 antibody (AA 200-300)
Quick Overview for Recombinant Syndecan 1 antibody (AA 200-300) (ABIN7871954)
Target
See all Syndecan 1 (SDC1) AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
Clone
-
-
Binding Specificity
- AA 200-300
-
Purpose
- Recombinant SDC1 Antibody / Syndecan-1 / CD138 (azide and preservative free)
-
Purification
- Protein A/G affinity
-
Immunogen
- A recombinant fragment (within amino acids 200-300) of human CD138 protein was used as the immunogen for the recombinant SDC1 antibody.
-
Isotype
- IgG1, kappa
-
-
-
-
Application Notes
- Optimal dilution of the recombinant SDC1 antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Preservative
- Azide free
-
Storage
- -20 °C
-
Storage Comment
- Aliquot the recombinant SDC1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- Syndecan 1 (SDC1)
-
Alternative Name
- SDC1
-
Background
- CD138, also designated syndecan-1, is a member of the syndecan family of four transmembrane spanning proteins capable of binding to heparan sulfate and chondroitin sulfate molecules. The syndecans main functions are to control cell growth and differentiation as well as to maintain cell adhesion and cell migration. Under normal conditions CD138 is predominantly expressed on mature plasma cells and early preB-cells, while other haematolymphoid cells are negative. Various types of epithelial cells are also CD138 positive. Squamous epithelial cells show strong membranous and some cytoplasmic staining, except for the mature superficial squamous epithelial cells which are unstained. Mature mesenchymal and neural tissues are not stained. Among haematolymphoid neoplasms, CD138 is expressed in practically all cases of plasma cell malignancies. Among non-haematolymphoid neoplasms the expression of CD138 is found in various types of carcinoma.
-
UniProt
- P18827
-
Pathways
- Glycosaminoglycan Metabolic Process, Regulation of Muscle Cell Differentiation, Skeletal Muscle Fiber Development, Lipid Metabolism
Target
-